A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

NCT03827200 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of recruitment, result of COVID-19 pandemic

Conditions

Cirrhosis
Portal Hypertension
Ascites

Interventions

DRUG: Ambrisentan

Sponsor

Noorik Biopharmaceuticals AG